Symposium: Helicobacter pylori and clinical risks-focus on gastro-oesophageal reflux disease

P. Malfertheiner, H. J. O'Connor, R. M. Genta, P. Unge, A. T R Axon

Research output: Contribution to journalArticle

  • 16 Citations

Abstract

Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease. The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori-gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks. Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser. Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalAlimentary Pharmacology and Therapeutics, Supplement
Volume16
Issue number3
StatePublished - 2002
Externally publishedYes

Fingerprint

Helicobacter pylori
Helicobacter Infections
Gastroesophageal Reflux
Axons
Marginal Zone B-Cell Lymphoma
Peptic Ulcer
Esophagus
Multicenter Studies
Stomach Neoplasms
Stomach
Prospective Studies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Symposium : Helicobacter pylori and clinical risks-focus on gastro-oesophageal reflux disease. / Malfertheiner, P.; O'Connor, H. J.; Genta, R. M.; Unge, P.; Axon, A. T R.

In: Alimentary Pharmacology and Therapeutics, Supplement, Vol. 16, No. 3, 2002, p. 1-10.

Research output: Contribution to journalArticle

Malfertheiner, P.; O'Connor, H. J.; Genta, R. M.; Unge, P.; Axon, A. T R / Symposium : Helicobacter pylori and clinical risks-focus on gastro-oesophageal reflux disease.

In: Alimentary Pharmacology and Therapeutics, Supplement, Vol. 16, No. 3, 2002, p. 1-10.

Research output: Contribution to journalArticle

@article{74bd222f2e2548ef83f4f1189941c9fb,
title = "Symposium: Helicobacter pylori and clinical risks-focus on gastro-oesophageal reflux disease",
abstract = "Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease. The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori-gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks. Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser. Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.",
author = "P. Malfertheiner and O'Connor, {H. J.} and Genta, {R. M.} and P. Unge and Axon, {A. T R}",
year = "2002",
volume = "16",
pages = "1--10",
journal = "Alimentary Pharmacology and Therapeutics, Supplement",
issn = "0953-0673",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Symposium

T2 - Alimentary Pharmacology and Therapeutics, Supplement

AU - Malfertheiner,P.

AU - O'Connor,H. J.

AU - Genta,R. M.

AU - Unge,P.

AU - Axon,A. T R

PY - 2002

Y1 - 2002

N2 - Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease. The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori-gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks. Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser. Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.

AB - Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease. The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori-gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks. Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser. Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.

UR - http://www.scopus.com/inward/record.url?scp=0036094921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036094921&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 1

EP - 10

JO - Alimentary Pharmacology and Therapeutics, Supplement

JF - Alimentary Pharmacology and Therapeutics, Supplement

SN - 0953-0673

IS - 3

ER -